Compare RGT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGT | ACRV |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.4M | 82.2M |
| IPO Year | N/A | 2022 |
| Metric | RGT | ACRV |
|---|---|---|
| Price | $14.45 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 11.7K | ★ 408.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | $15.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $1.15 |
| 52 Week High | $14.99 | $3.56 |
| Indicator | RGT | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 41.40 |
| Support Level | $13.95 | $1.46 |
| Resistance Level | $14.83 | $2.22 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.41 | 32.18 |
Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.